Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02835833
Title Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Alabama at Birmingham

lung non-small cell carcinoma

ovarian carcinoma

renal cell carcinoma

colorectal adenocarcinoma

cervix carcinoma


Bevacizumab + Nintedanib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.